Skip to Content
Merck
  • Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.

Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.

The journal of physical chemistry. B (2014-07-31)
Niraj S Trasi, Jared A Baird, Umesh S Kestur, Lynne S Taylor
ABSTRACT

Amorphous forms of drugs are increasingly being used to deliver poorly water-soluble compounds. Therefore, understanding the magnitude and origin of differences in crystallization kinetics is highly important. The goal of this study was to better understand the factors that influence crystal growth rates from pharmaceutically relevant undercooled liquids and to evaluate the range of growth rates observed. The crystal growth rates of 31 drugs were determined using an optical microscope in the temperature region between the glass transition temperature (Tg) and the melting temperature (Tm). Thermodynamic parameters such as Tm, melting enthalpy, and Tg were determined using a differential scanning calorimeter (DSC). Selected viscosity values for the undercooled liquid were taken from the literature. The growth rates of the different compounds were found to be very different from each other with a variation of about 5 orders of magnitude between the fastest growing compounds and the slowest growing compounds. A comparison of the physicochemical properties showed that compounds that had fast crystal growth rates had smaller molecular weights, higher melting temperatures, lower melt entropies, lower melt viscosities, and higher crystal densities. Variations in the growth rates of the compounds could be rationalized to a large extent by considering the thermodynamic driving force for crystallization, the viscosity, and the entropy difference between the melt and undercooled liquid. This study therefore provides important insight into factors that may compromise the stability of amorphous pharmaceuticals.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acetaminophen, BioXtra, ≥99.0%
Sigma-Aldrich
Acetaminophen, meets USP testing specifications, 98.0-102.0%, powder
Sigma-Aldrich
Acetaminophen, analytical standard
Sigma-Aldrich
Flurbiprofen, cyclooxygenase inhibitor
Sigma-Aldrich
Clotrimazole
Sigma-Aldrich
Ketoprofen, ≥98% (TLC)
Sigma-Aldrich
Pimozide
Supelco
Tolbutamide, analytical standard
Sigma-Aldrich
Nilutamide, solid
Sigma-Aldrich
Piroxicam, meets USP testing specifications
Sigma-Aldrich
Piroxicam, ≥98% (TLC)
Sigma-Aldrich
Cinnarizine, powder
Sigma-Aldrich
Nimesulide
Sigma-Aldrich
Droperidol
Sigma-Aldrich
Ketoprofen, meets USP testing specifications
Sigma-Aldrich
Bifonazole, ≥98% (HPLC)
USP
Clozapine Resolution Mixture, United States Pharmacopeia (USP) Reference Standard
Supelco
Bifonazole, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Nimesulide, Pharmaceutical Secondary Standard; Certified Reference Material
Pimozide, European Pharmacopoeia (EP) Reference Standard
Ketoprofen, European Pharmacopoeia (EP) Reference Standard
Clozapine for peak identification, European Pharmacopoeia (EP) Reference Standard
Clotrimazole for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Acetaminophen solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Droperidol, European Pharmacopoeia (EP) Reference Standard
Cinnarizine, European Pharmacopoeia (EP) Reference Standard
Nilutamide, European Pharmacopoeia (EP) Reference Standard
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
Miconazole, European Pharmacopoeia (EP) Reference Standard
USP
Clotrimazole, United States Pharmacopeia (USP) Reference Standard